Discussion about this post

User's avatar
Darcy Lewis's avatar

I salute you and, in true Annie fashion, you've done a lot of good work in a short time. I don't think I knew that this was your fathers' and aunt's diagnosis--how awful. I'm currently working on a story about diffuse midline gliomas (DMGs) and have two tiny little rays of light to share. First, you probably know that brain tumor researchers are an incredibly close group. They have to be as the diseases they study are so rare and the emotional toll of their work is so high. I typically get one study author and one unaffiliated expert to comment on a given study and that is essentially impossible to do in the pediatric brain tumor space because they pretty much all participate in every trial that comes along. The other piece of good news is that the first-ever drug for DMGs with a specific (most common) mutation has recently gotten accelerated FDA approval based on six phase I/II trials. 22% of patients responded to the drug and had responses lasting several months. Some phase III trials are underway. In any other disease group, these would be disappointing but here, this is cause for celebration.

Expand full comment
Karen Kroll's avatar

Thank you for your commitment and efforts. They will make a difference.

Expand full comment
5 more comments...

No posts